Regulus Therapeutics, Inc. (RGLS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159837,
    "name": "Regulus Therapeutics, Inc.",
    "stock_name": "Regulus Therapeutics, Inc.",
    "full_name": "Regulus Therapeutics, Inc.",
    "name_url": "stocks-analysis/regulus-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.16",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "8.16",
    "mcapval": "534.48",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US75915K3095",
    "curr_date": "Jun 26",
    "curr_time": "",
    "bse_nse_vol": "0 ",
    "exc_status": "Active",
    "traded_date": "Jun 26, 2025",
    "traded_date_str": "2025 06 26",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/regulus-therapeutics-inc-1159837-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Regulus Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regulus-therapeutics-inc-technically-bullish-or-bearish-3546912",
        "imagepath": "",
        "date": "2025-09-20 19:42:55",
        "description": "As of 27 May 2025, the technical trend for Regulus Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD (both weekly and monthly), Bollinger Bands (weekly and monthly), KST (weekly and monthly), and moving averages (daily). However, the RSI indicates bearish momentum on both the weekly and monthly time frames, and Dow Theory shows a bearish signal on the weekly chart with no trend on the monthly.\n\nIn terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 416.46% compared to the S&P 500's 12.22%, and over the past year, it has returned 300.0% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is Regulus Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regulus-therapeutics-inc-overvalued-or-undervalued-3543389",
        "imagepath": "",
        "date": "2025-09-20 18:18:05",
        "description": "As of 11 March 2022, the valuation grade for Regulus Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 8.24 and an EV to Capital Employed ratio of 120.55, which suggests that the market is pricing the company at a premium despite its poor financial performance. Additionally, the negative ROCE of -1237.25% and ROE of -68.85% further highlight the challenges the company faces.\n\nIn comparison to its peers, Regulus Therapeutics, Inc. has a less favorable EV to EBITDA ratio of -9.81, while BeyondSpring, Inc. and Aligos Therapeutics, Inc. have ratios of -7.9578 and 0.6671, respectively, indicating that Regulus is underperforming relative to these competitors. Despite its recent strong returns, with a year-to-date stock return of 416.46% compared to the S&P 500's ..."
      }
    ],
    "total": 7,
    "sid": "1159837",
    "stock_news_url": "https://www.marketsmojo.com/news/regulus-therapeutics-inc-1159837"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Regulus Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:42:55

As of 27 May 2025, the technical trend for Regulus Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD (both weekly and monthly), Bollinger Bands (weekly and monthly), KST (weekly and monthly), and moving averages (daily). However, the RSI indicates bearish momentum on both the weekly and monthly time frames, and Dow Theory shows a bearish signal on the weekly chart with no trend on the monthly. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 416.46% compared to the S&P 500's 12.22%, and over the past year, it has returned 300.0% versus the S&P 500's 17.14%....

Is Regulus Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:18:05

As of 11 March 2022, the valuation grade for Regulus Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 8.24 and an EV to Capital Employed ratio of 120.55, which suggests that the market is pricing the company at a premium despite its poor financial performance. Additionally, the negative ROCE of -1237.25% and ROE of -68.85% further highlight the challenges the company faces. In comparison to its peers, Regulus Therapeutics, Inc. has a less favorable EV to EBITDA ratio of -9.81, while BeyondSpring, Inc. and Aligos Therapeutics, Inc. have ratios of -7.9578 and 0.6671, respectively, indicating that Regulus is underperforming relative to these competitors. Despite its recent strong returns, with a year-to-date stock return of 416.46% compared to the S&P 500's ...

View All News